A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma.
from News Medical Medical Research News Feed https://ift.tt/IJDMWxQ
0 Comments